Patient preferences for managing asthma: Results from a discrete choice experiment

Health Economics

Volumn 16, Issue 7, 2007, Pages 703-717

  King, Madeleine T ^a   Hall, Jane ^a   Lancsar, Emily ^b   Fiebig, Denzil ^a,c   Hossain, Ishrat ^a   Louviere, Jordan ^a,d   Reddel, Helen K ^e   Jenkins, Christine R ^e  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b NEWCASTLE UNIVERSITY BUSINESS SCHOOL   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Asthma; Discrete choice experiments; Mixed logit; Preventive medications; Stated preferences

Indexed keywords

FLUTICASONE; FORMOTEROL; MONTELUKAST; PLACEBO; SALBUTAMOL;

ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CROSSOVER PROCEDURE; DAILY LIFE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG PREFERENCE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPORT; STATISTICAL ANALYSIS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; AUSTRALIA; CHOICE BEHAVIOR; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; FEES, PHARMACEUTICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PATIENT SATISFACTION; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 34547110409     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1193     Document Type: Article

References (40)

1. Adams RJ, Fuhlbrigge A, Guilbert T, Lozano P, Martinez F. 2002. Inadequate use of asthma medication in the United States: results of the asthma in America national population survey. J Allergy Clin Immunol 110: 58-64. DOI:10.1067/mai.2002.125489
2. Andrews DWK. 1998. Hypothesis testing with a restricted parameter space. J Econometrics 84: 155-199. DOI:10.1016/ S0304-4076(97)00083-3
3. Australian Institute of Health & Welfare. 2000. Australia's Health 2000: The Seventh Biennial Health Report of the Australian Institute of Health and Welfare. Australian Institute of Health & Welfare: Canberra.
4. Balsbaugh TA, Chambers CV, Diamond JJ. 1999. Asthma controller medications: What do patients want? J Asthma 36: 591-596.
5. Barnes PJ, Jonsson B, Klim JB. 1996. The costs of asthma. Eur Respir J 9: 636-642. DOI:10.1183/09031936.96.09040636
6. British Thoracic Society, Scottish Intercollegiate Guidelines Network. 2004. British Guideline on the Management of Asthma: A National Clinical Guideline. British Thoracic Society; Scottish Intercollegiate Guidelines Network: London.
7. Brownstone D, Train K. 1999. Forecasting new product penetration with flexible substitution patterns. J Econometrics 89: 102-129.
8. Bukstein DA, Bratton DL, Firriolo KM et al. 2003. Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study. J Asthma 40: 475-485. DOI:10.1081/JAS-120018714
9. Ducharme FM, Hicks GC. 2000. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma. [Update in Cochrane Database Syst Rev. 2002;(3):Cd002314; pmid: 12137655]. Cochrane Database of Systematic Reviews, CD002314.
10. Garratt AM, Hutchinson A, Russell I. 2000. Patient-assessed measures of health outcome in asthma: a comparison of four approaches. Respir Med 94: 597-606. DOI:10.1053/rmed.2000.0787
11. Holman H, Lorig K. 2000. Patients as partners in managing chronic disease. Partnership is a prerequisite for effective and efficient health care. Br Med I 320: 526-527. DOI:10.1136/ bmj.320.7234.526
12. Jenkins C, Thien K, Weatley J, Reddel H. 2005. Traditional and patient-centred outcomes with three classes of asthma medication. Eur Respir J 26: 36-44. DOI:10.1183/09031936.05.00144704
13. Johansson G, Stallberg B, Tornling G et al. 2004. Asthma treatment preference study: A conjoint analysis of preferred drug treatments. Chest 125: 916-923. DOI:10.1378/chest.125.3.916
14. Jones PW. 1995. Quality of life, health economics and asthma. Eur Respir Rev 5: 279-283.
15. Kelloway JS, Wyatt RA, Adlis SA. 1994. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 154: 1349-1352. DOI:10.1001/archinte.154.12.1349
16. Kievit P, Sculpher M, Williams A. 2004. Understanding the patient's perspective of asthma control. Eur Respir Rev 13: 110-112.
17. Krahn MD, Berka C, Langlois P, Detsky AS. 1996. Direct and indirect costs of asthma in Canada, 1990. Can Med Assoc J 154: 821-831.
18. Lancsar E, Savage E. 2004. Deriving welfare measures from discrete choice experiments: Inconsistencies between current methods and random utility and welfare theory. Health Econ 13: 901-907. DOI:10.1002/hec.870
19. Louviere JJ, Hensher DA, Swait JD. 2000. Stated Choice Methods: Analysis and Applications. Cambridge University Press: Cambridge.
20. Marks GB, Dunn SM, Woolcock AJ. 1992. A scale for the measurement of quality of life in adults with asthma. J Clin Epidemiol 45: 461-472. DOI:10.1016/0895-4356(92)90095-5
21. Marks GB, Jalaludin BB, Williamson M, Atkin NL, Bauman A. 2000. Use of 'preventer' medications and written asthma management plans among adults with asthma in New South Wales. Med J Aust 173: 407-410.
22. Markson LE, Vollmer WM, Fitterman L et al. 2001. Insight into patient dissatisfaction with asthma treatment. Arch Intern Med 161: 379-384. DOI:10.1001/archinte.161.3.379
23. McFadden D. 1981. Econometric models of probabilistic choice. In Structural Analysis of Discrete Data with Economic Applications, Manski CF, McFadden D (eds), MIT Press: Boston, 422-434.
24. McFadden D, Train K. 2000. Mixed MNL models for discrete response. J Appl Econom 15: 447-470. DOI:10.1002/1099-1255(200009/ 10)15:5<447::AID-JAE570>3.3.CO;2-T
25. Osman LM, McKenzie L, Cairns J et al. 2001. Patient weighting of importance of asthma symptoms. Thorax 56: 138-142. DOI:10.1136/thorax.56.2.138
26. Rabe KF, Vermeire PA, Soriano JB, Maier WC. 2000. Clinical management of asthma in 1999: the asthma insights and reality in Europe (aire) study. Eur Respir J 16: 802-807. DOI:10.1183/09031936.00.16580200
27. Revelt D, Train K. 1998. Mixed logit with repeated choices: households' choices of appliance efficiency level. Rev Econ Stat 80: 647-657. DOI:10.1162/003465398557735
28. Rutten-Van Molken M, Kerstjens HAM. 1996. Combination of inhaled corticosteroids and beta2-agonists in asthma. Clinical and economic implications. Clin Immunother 6: 489-505.
29. Rutten-van Molken MP, Postma MJ, Joore MA, Van Genugten ML, Leidl R, Jager JC. 1999. Current and future medical costs of asthma and chronic obstructive pulmonary disease in the Netherlands. Respir Med 93: 779-787.
30. Rutten van-Molken MP, Feenstra TL. 2001. The burden of asthma and chronic obstructive pulmonary disease: data from the Netherlands. Pharmacoeconomics 19: 1-6. DOI:10.2165/ 00019053-200119002-00001
31. Salkeld G, Ryan M, Short L. 2000. The veil of experience: do consumers prefer what they know best? Health Econ 9: 267-270. DOI:10.1002/(SICI)1099-1050(200004)9:3<267::AID-HEC511>3.0.CO;2-H
32. Smith DH, Malone DC, Lawson KA, Okamoto LJ, Battista C, Saunders WB. 1997. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 156: 787-793.
33. Szucs TD, Anderhub H, Rutishauser M. 1999. The economic burden of asthma: Direct and indirect costs in switzerland. Eur Respir J 13: 281-286. DOI:10.1034/j.1399-3003.1999.13b10.x
34. Tettersell MJ. 1993. Asthma patients' knowledge in relation to compliance with drug therapy. J Adv Nurs 18: 103-113. DOI:10.1046/j.1365-2648.1993.18010103.x
35. Train K. Mixed logit estimation for panel data using maximum simulated likelihood website. http://elsa.berkeley.edu/Software/abstracts/ train0296.html [15 December 2004].
36. Train K. 2003. Discrete Choice Methods With Simulation. Cambridge University Press: New York.
37. Viney R, Lancsar E, Louviere J. 2002. Discrete choice experiments to measure consumer preferences for health and healthcare. Expert Rev Pharmaco Outcomes Res 2: 319-326. DOI:10.1586/14737167.2.4.319
38. Weinberg EG, Naya I. 2000. Treatment preferences of adolescent patients with asthma. Pediatr Allergy Immunol 11: 49-55. DOI:10.1034/j.1399-3038.2000.00043.x
39. Wilson DH, Adams RJ, Appleton SL et al. 2003. Prevalence of asthma and asthma action plans in South Australia: population surveys from 1990 to 2001. Med J Aust 178: 483-485.
40. Wilson N. 2001. The cost burden of asthma in New Zealand. N Z Med J 114: 146-147.